INNO-206 is an albumin-binding prodrug of Doxorubicin developed to improve the therapeutic effects of Doxorubicin and to decrease the toxicities. In this randomized Phase II study patients with metastatic, locally advanced, or unresectable soft tissue sarcoma will receive INNO-206 or Docorubicin intravenously once every 3 weeks.
Yondelis is an anticancer agent discovered from the sea squirt, Ecteinascidia turbinate that is now produced synthetically. It binds to DNA resulting in DNA damage within cancer cells and leading to their death. In this randomized Phase III study Yondelis or Decarbazine is given to patients with advanced liposarcoma or leiomyosarcoma who have previously received the standard chemotherapies anthracycline and ifosfamide.